• Meridian Bioscience Inc (NASDAQ: VIVO) has agreed to acquire the North American BreathTek business from Otsuka America Pharmaceutical Inc for $20 million in cash.

• The transaction will close in Meridian's fiscal fourth quarter, which ends in September.

• With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test to detect Helicobacter pylori.

• Meridian expects the acquisition to add more than $20 million of annual revenue, enhancing its diagnostics segment. The deal will be accretive to earnings and cash immediately.

• As of 31 March, the company reported cash and cash equivalents were .4 million and $110 million of borrowing capacity under its $160.0 million commercial bank credit facility.

• Price Action: VIVO shares are up 0.21% at $18.98 during the market session on the last check Friday.

See more from Benzinga

• Click here for options trades from Benzinga

• Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations

• Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.